Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077882 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| SCHEMBL8198672 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| Hydrochloric Acid SCHEMBL336873 | 0.98 | CHRNB2 (0.46) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| Hydrochloric Acid SCHEMBL4062254 | 0.98 | CHRNB2 (0.46) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| Hydrochloric Acid SCHEMBL21801329 | 0.98 | CHRNB2 (0.46) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| SCHEMBL21509270 | 0.94 | CYP1A2 (0.48) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| SCHEMBL13333879 | 0.94 | CYP1A2 (0.48) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| Hydrochloric Acid SCHEMBL6498891 | 0.92 | CYP1A2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5FFAR1 | |
| SCHEMBL19343119 | 0.87 | — | — | |
| SCHEMBL27000151 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| WO-2020052631-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | WO | disclosed |
| WO-2018134842-A1 | PROCESS FOR THE PREPARATION OF CARBAMIC ACID, N,N'-[[1,1'-BIPHENYL] -4,4'-DIYLBIS]- 1 H-IMIDAZOLE-5,2 DIYI-(2S)-2,1-PYRROLIDINEDIYL[(1 S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL]]] BIS-,C,C'-DIMETHYL ESTER AND ITS SALTS AND POLYMORPHS | MSN LABORATORIES PRIVATE LIMITED, R & D CENTER (IN) | 2018-07-26 | — | — | WO | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | UGT2B7, CYP3A7, CYP3A43 | CHRNB2 3462/4885CHRNA7 2834/4885CHRNA4 3927/4885 |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | CHRNB2 633/4885CHRNA7 483/4885CHRNA4 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.